Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kaftrio

- PMLiVE

FDA approves two cell-based gene therapies for sickle cell disease

Vertex/CRISPR and bluebird bio’s gene therapies have been approved to treat patients aged 12 years and older

- PMLiVE

Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults

RSV is associated with 15,000 hospital admissions in infants under six months every year in England

- PMLiVE

MHRA extends licence of Vertex’s cystic fibrosis drugs for young children

Kaftrio and Kalydeco are now approved for use in certain patients aged two to five years

- PMLiVE

MHRA authorises world-first gene therapy for two inherited blood disorders

Casgevy is now the first licensed treatment that uses the gene-editing tool CRISPR

- PMLiVE

Eli Lilly’s tirzepatide injection approved by MHRA and FDA for weight loss in adults

The drug has been authorised for use alongside a reduced-calorie diet and physical activity

- PMLiVE

MHRA authorises anastrozole to prevent breast cancer in post-menopausal women

The treatment could help prevent around 2,000 breast cancer cases in England

- PMLiVE

Pfizer’s Litfulo approved by MHRA for adults and adolescents with alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

FDA completes meeting for potential genetic therapy to treat sickle cell disease

If approved, exa-cel will be the first genetic therapy available to treat patients with severe sickle cell disease

- PMLiVE

Moderna’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

The vaccine has been updated to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Bristol Myers Squibb’s Sotyktu approved by MHRA for plaque psoriasis

Up to 1.8 million people in the UK are affected by some form of the inflammatory condition

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links